Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAINER-2: Short-Course Radiotherapy, CAPOX, Bevacizumab +/- Toripalimab as Total Neoadjuvant Therapy for Rectal Cancer
NCT07198165Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in rectal cancer, sponsored by Ruijin Hospital. Started Sep 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07198165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198165.